ODYY · XBRL financial data

Odyssey Health financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ODYY's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Research and development	26	43	0	(11)*	0	0	0	0*	—	—	—	year only
General and administrative	501	437	321	247*	520	120	117	264*	303	182	298	130*
Operating income (loss)	(847)	(1,157)	(372)	16,638*	(580)	(157)	(129)	(156)*	(303)	(182)	(298)	(130)*
Interest expense	191	142	102	84*	69	63	61	59*	95	412	528	548*
Other income (expense)	0	9	0	0*	0	(0)	0	(10)*	0	(10)	0	0*
Income tax expense (benefit)	—	—	—	year only	—	—	—	year only	—	—	—	year only
Net income (loss)	(538)	13,278	(842)	(12,740)*	(1,019)	(220)	(252)	(252)*	(483)	(3,602)	766	(2,411)*
Earnings per share, basic USD per share	(0.01)	0.14	(0.01)	(0.11)*	(0.01)	0.00	0.00	0.00*	0.00	(0.03)	0.01	(0.02)*
Earnings per share, diluted USD per share	(0.01)	0.12	(0.01)	(0.14)*	(0.01)	0.00	0.00	0.00*	0.00	(0.03)	0.01	—
Weighted average shares, basic thousands of shares	81,022	91,975	103,789	111,615*	104,710	104,710	104,710	104,710*	106,037	107,854	108,031	111,360*
Weighted average shares, diluted thousands of shares	81,022	114,056	103,789	89,534*	104,710	104,710	104,710	104,710*	106,037	107,854	186,675	—

Fiscal quarters (ODYY's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Cash and cash equivalents	198	166	66	2	54	7	3	19	26	616	298	122
Prepaid and other current assets	74	71	65	32	129	101	64	31	118	105	76	25
Total current assets	563	259	153	57	183	108	67	50	144	721	374	148
Total assets	612	14,050	13,576	586	341	267	165	50	144	721	374	148
Accounts payable	1,851	1,266	1,297	1,276	1,458	1,453	1,478	1,615	1,689	1,620	1,485	712
Total current liabilities	6,830	5,379	5,696	5,920	6,620	6,730	6,867	7,004	7,299	11,317	10,123	12,278
Accumulated deficit	(60,635)	(47,421)	(48,264)	(61,003)	(62,022)	(62,242)	(62,494)	(62,746)	(63,229)	(66,831)	(66,065)	(68,476)
Total stockholders' equity	(6,218)	8,670	7,880	(5,334)	(6,279)	(6,463)	(6,703)	(6,955)	(7,155)	(10,596)	(9,750)	(12,130)
Total liabilities and equity	612	14,050	13,576	586	341	267	165	50	144	721	374	148
Common shares outstanding (cover page) thousands of shares	83,124	96,360	96,360	96,710	96,710	96,710	96,710	99,854	99,854	99,854	100,969	110,219

Fiscal quarters (ODYY's year ends in late July)

In thousands of dollars	Q1 FY24Oct 31, 2023	Q2 FY24Jan 31, 2024	Q3 FY24Apr 30, 2024	Q4 FY24Jul 31, 2024	Q1 FY25Oct 31, 2024	Q2 FY25Jan 31, 2025	Q3 FY25Apr 30, 2025	Q4 FY25Jul 31, 2025	Q1 FY26Oct 31, 2025	Q2 FY26Jan 31, 2026	Q3 FY26Apr 30, 2026	Q4 FY26Jul 31, 2026
Net income (loss)	(538)	13,278	(842)	(12,740)*	(1,019)	(220)	(252)	(252)*	(483)	(3,602)	766	(2,411)*
Stock-based compensation	323	677*	51*	(474)*	60	36*	12*	0*	0	0*	0*	5*
Net cash from operating activities	(60)	(908)*	(184)*	(64)*	(249)	(47)*	(4)*	(48)*	(284)	(284)*	(319)*	(160)*
Net cash from investing activities	0	1,000*	0*	0*	—	—	0*	70*	—	—	—	year only
Proceeds from issuing equity	46	10*	0*	0*	0	0*	0*	0*	—	—	—	—
Net cash from financing activities	221	(124)*	84*	0*	300	0*	0*	(6)*	291	875*	0*	(16)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Odyssey Health	122	not reported	(160)*	110.2M	0.8 quarters	Q4 FY26 10-KJul 31, 2026
Autonomix Medical	3,460	0	(3,544)	971,043	1.0 quarters	Q1 FY27 10-QJun 30, 2026
Sonoma Pharmaceuticals	5,338	6,406	(649)	4.8M	8.2 quarters	Q1 FY27 10-QJun 30, 2026
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
Adm Tronics Unlimited	223	not reported	(33)	67.6M	6.8 quarters	Q1 FY26 10-QJun 30, 2026
Aethlon Medical	4,934	not reported	(1,897)	711,136	2.6 quarters	Q1 FY27 10-QJun 30, 2026
Glucotrack	1,124	not reported	(3,616)*	10.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026
SeaStar Medical Holding	6,959	615	(2,994)*	4.4M	2.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.